<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639223</url>
  </required_header>
  <id_info>
    <org_study_id>806827</org_study_id>
    <nct_id>NCT00639223</nct_id>
  </id_info>
  <brief_title>Safety of Red Yeast Rice for High Cholesterol in Individuals With Statin Intolerance</brief_title>
  <official_title>Red Yeast Rice vs. Pravastatin: A Double-Blind Randomized Comparative Study of Myopathic Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chestnut Hill Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effect of red yeast rice extract compared to pravastatin on
      muscle related complaints in individuals with high cholesterol who have previously been
      unable to tolerate statin medications due to muscle pain. The study will determine whether
      red yeast is associated with a lower level of muscle related complaints compared to
      pravastatin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      20 million Americans are actively treated with statins at an annual cost of 16 billion
      dollars. Statins are effective therapeutic agents for reducing LDL cholesterol and have
      documented effectiveness. However, a significant subset of patients (5-18%), cannot tolerate
      lipid lowering statin therapy due to intolerable muscle-related symptoms characterized by
      muscle pain and/or weakness. These symptoms affect quality of life and lead to poor
      adherence.

      Patients may seek alternative therapies to manage hypercholesterolemia if they have been
      intolerant of statin therapy. One commonly used alternative treatment option is the Chinese
      herb red yeast rice extract. Several small studies performed in China, have suggested this
      treatment is efficacious and well tolerated. In the U.S. red yeast rice is sold over the
      counter a dietary supplement.

      The objective of this study is to critically examine the safety and efficacy of the Chinese
      herb red yeast rice as an alternative lipid lowering therapy, in a statin intolerant
      population.

      This objective will be operationalized by a double-blind randomized trial, comparing the
      effect of red yeast rice extract, to that of pravastatin on the level of myalgia in subjects
      with a prior history of statin-induced myalgias.

      The specific aims include:

        1. Determine the relative rates of withdrawal from treatment in subjects receiving red
           yeast rice compared to pravastatin.

        2. Determine if red yeast rice is associated with a lower level of muscle pain (myalgia)
           symptoms compared to pravastatin as measured by the Brief Pain Inventory, a validated
           pain questionnaire.

        3. Determine if red yeast rice is associated with a lower level of muscle weakness compared
           to pravastatin as measured by a dynamometry, a validated muscle strength testing method.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Withdrawal of Therapy Due to Muscle Symptoms That Are Either Intolerable and/or Associated With a Creatine Kinase(CK) &gt;500</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-Cholesterol Measured at the Beginning and End of the Study</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Statin-Associated Myopathy</condition>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Red yeast Rice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Red Yeast Rice</intervention_name>
    <description>Four 600mg capsules twice daily for 12 weeks</description>
    <arm_group_label>Red yeast Rice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>One 20mg capsule twice daily for 12 weeks</description>
    <arm_group_label>Pravastatin</arm_group_label>
    <other_name>Pravachol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle modification program</intervention_name>
    <description>Weekly sessions each lasting 3 1/2 hours for 12 weeks</description>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_label>Red yeast Rice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject reports stopping at least one statin drug due to complaints of muscle pain or
             weakness which his/her physician thinks was attributable to the drug.

          -  Subject has never taken pravastatin.

          -  Subject willing to remain off the dietary supplements CoQ10, L-carnitine, fish oil,
             policosanol, and guggulipid, garlic, and phytosterols in margarines (e.g. Benecol,
             Promise activ), milk or cereal products, for one month prior to the trial and for the
             duration of the trial.

        Exclusion Criteria:

          -  A history of muscle damage (CK&gt;1000 IU) on statin therapy.

          -  A history of generalized chronic pain such as fibromyalgia, or generalized arthritis.

          -  Any active cardiac problem including chest pain, angina, heart attack, bypass surgery,
             angioplasty/stent or unstable angina/acute coronary syndrome within the past 6 months.

          -  Taking other lipid lowering drugs including: ezetimibe, gemfibrozil, niacin, fibrates
             or bile acid sequestrants.

          -  Triglyceride level more than 400 mg/dl.

          -  Taking weight loss medication including orlistat, sibutramine, diethylpropion,
             phendimetrazine, phentermine.

          -  Taking pain medication or systemic steroids on a chronic basis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven C Halbert, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chestnut Hill Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <results_first_submitted>December 9, 2009</results_first_submitted>
  <results_first_submitted_qc>December 9, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2010</results_first_posted>
  <last_update_submitted>December 9, 2009</last_update_submitted>
  <last_update_submitted_qc>December 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>David Becker MD Principal Investigator</name_title>
    <organization>Chestnut Hill Health System</organization>
  </responsible_party>
  <keyword>Statin related myalgia</keyword>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Red yeast rice</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Nutritional and Metabolic Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Red yeast rice</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pravastatin</title>
        </group>
        <group group_id="P2">
          <title>Red Yeast Rice</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pravastatin</title>
        </group>
        <group group_id="B2">
          <title>Red Yeast Rice</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.9" spread="6.6"/>
                    <measurement group_id="B2" value="62.4" spread="8.9"/>
                    <measurement group_id="B3" value="62.7" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Withdrawal of Therapy Due to Muscle Symptoms That Are Either Intolerable and/or Associated With a Creatine Kinase(CK) &gt;500</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pravastatin</title>
          </group>
          <group group_id="O2">
            <title>Red Yeast Rice</title>
          </group>
        </group_list>
        <measure>
          <title>Withdrawal of Therapy Due to Muscle Symptoms That Are Either Intolerable and/or Associated With a Creatine Kinase(CK) &gt;500</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL-Cholesterol Measured at the Beginning and End of the Study</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pravastatin</title>
          </group>
          <group group_id="O2">
            <title>Red Yeast Rice</title>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL-Cholesterol Measured at the Beginning and End of the Study</title>
          <units>Percentage Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.0" spread="15.4"/>
                    <measurement group_id="O2" value="-30.2" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pravastatin</title>
        </group>
        <group group_id="E2">
          <title>Red Yeast Rice</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal bloating or gas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size precluded definitive conclusions.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Steven Halbert MD, MSCE</name_or_title>
      <organization>U. of Pennsylvania Health System</organization>
      <phone>215 510 2221</phone>
      <email>shalbert@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

